Skip to main content
SRZN
NASDAQ Life Sciences

10% Owner TCG Crossover Funds Increase Stake in Surrozen with $1.22M Open Market Purchase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$25.5
Mkt Cap
$218.571M
52W Low
$5.9
52W High
$29.595
52W Position info
332% above low
Off High info
14% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

SRZN has more than doubled off its 52-week low of $5.9 on light trading volume (0.3× avg).

Summary

TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., along with their general partners, collectively increased their holdings in Surrozen, Inc. through open market purchases totaling over $1.22 million.


Key Events · Ownership and Investor Activity · SRZN

  • Significant Insider Purchase

    TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., both 10% owners, collectively purchased 48,997 shares of Surrozen, Inc. common stock.

  • Substantial Investment

    The open market purchases totaled $1,220,362, executed across six transactions between March 12 and March 16, 2026, at prices ranging from $24.88 to $24.99 per share.

  • Continued Accumulation

    This transaction adds to a pattern of insider accumulation, with net insider buys totaling $647,379 in the 90 days prior to this filing, indicating ongoing investor confidence.


Analysis · SRZN · Life Sciences

This Form 4 filing indicates a significant vote of confidence from a major institutional investor. TCG Crossover Funds, identified as 10% owners, acquired over $1.22 million worth of Surrozen common stock through multiple open market transactions between March 12 and March 16, 2026. While 10% owners are financial investors rather than operational insiders, such a substantial purchase suggests a positive outlook on the company's prospects and could be interpreted as a bullish signal for other investors. This purchase contributes to a broader pattern of insider accumulation observed over the last 90 days.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRZN was trading at $25.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $218.6M. The 52-week trading range was $5.90 to $29.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRZN - Latest Insights

SRZN
Nov 13, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $32.05
Real-time Price: $30.67 info
Change: -$1.38 (-4%) info
Market Cap: $584.621M info
SRZN
Nov 09, 2026, 4:59 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $30.67 info
Change: -$1.33 (-4%) info
Market Cap: $584.621M info
SRZN
Nov 09, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $30.67 info
Change: -$1.33 (-4%) info
Market Cap: $584.621M info
SRZN
Nov 09, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $30.67 info
Change: -$1.33 (-4%) info
Market Cap: $584.621M info
SRZN
Oct 20, 2026, 4:59 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $25.14
Real-time Price: $30.67 info
Change: +$5.53 (+22%) info
Market Cap: $584.621M info